YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Development of a Quantitative ELISA for Anti HER-2 Antibodies using Human HER-2 Recombinant Proteins

인간 HER-2 재조합 단백질을 사용한 항 HER-2 항체 단백질의 ELISA 정량 방법 개발

  • Jung, Sun-Ki (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University) ;
  • Ryu, Chang-Seon (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University) ;
  • Choung, Kyu-Jin (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University) ;
  • Song, Gyu-Yong (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University) ;
  • Kim, Sang-Kyum (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University)
  • 정선기 (충남대학교 약학대학, 충남대학교 형질전환복제돼지센터) ;
  • 류창선 (충남대학교 약학대학, 충남대학교 형질전환복제돼지센터) ;
  • 정규진 (충남대학교 약학대학, 충남대학교 형질전환복제돼지센터) ;
  • 송규용 (충남대학교 약학대학, 충남대학교 형질전환복제돼지센터) ;
  • 김상겸 (충남대학교 약학대학, 충남대학교 형질전환복제돼지센터)
  • Received : 2010.10.12
  • Accepted : 2010.11.25
  • Published : 2011.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

HER-2 (Human Epidermal Growth Factor Receptor-2) is a protein giving higher aggressiveness in human breast cancers. Trastuzumab is a monoclonal antibody that targets HER-2 and is known to extend survival across all stages of HER2-positive breast cancer. In this study, we attempted to development of a quantitative ELISA (Enzyme-Linked ImmunoSorbent Assay) for evaluating anti HER-2 antibodies using human HER-2 recombinant proteins to support antibody producing processes and pharmacokinetic studies. We established direct or indirect ELISA method for the trastuzumab-like protein combined human recombinant HER-2. The ELISA method will prove to be great value in quantitating anti-HER-2 antibodies levels for developing anticancer antibodies.

Keywords

References

  1. King, C. R., Kraus, M. H. and Aaronson, S. A. : Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229, 974 (1985). https://doi.org/10.1126/science.2992089
  2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire, W. L. : Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177 (1987). https://doi.org/10.1126/science.3798106
  3. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R. and Aaronson S. A. : erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178 (1987). https://doi.org/10.1126/science.2885917
  4. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G. and Keith, D. E. : Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707 (1989). https://doi.org/10.1126/science.2470152
  5. Moasser, M. M. : The oncogene HER-2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469 (2007). https://doi.org/10.1038/sj.onc.1210477
  6. Press, M. F. and Lenz, H. J. : EGFR, HER-2 and VEGF pathways, validated targets for cancer treatment. Drugs 67, 2045 (2007). https://doi.org/10.2165/00003495-200767140-00006
  7. Hortobagyi, G. N. : Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 28(6 Suppl 18), 43 (2001). https://doi.org/10.1053/sonc.2001.29710
  8. Clynes, R. A., Towers, T. L. and Presta, L. G. : Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443 (2000). https://doi.org/10.1038/74704
  9. Maple, L., Lathrop, R., Bozich, S., Harman, W., Tacey, R., Kelley, M. and Danilkovitch-Miagkova, A. : Development and validation of ELISA for Herceptin detection in human serum. J. Immunol. Methods 295, 169 (2004). https://doi.org/10.1016/j.jim.2004.09.012
  10. Sias, P. E., Kotts, C. E., Vetterlein, D., Shepard, M. and Wong, W. L. : ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J. Immunol. Methods 132, 73 (1990). https://doi.org/10.1016/0022-1759(90)90400-P
  11. Piechocki, M. P., Pilon, S. A. and Wei, W. Z. : Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J. Immunol. Methods 259, 33 (2002). https://doi.org/10.1016/S0022-1759(01)00487-2
  12. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C. and Norton, L. : Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737 (1996). https://doi.org/10.1200/JCO.1996.14.3.737
  13. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A. and Slamon, D. J. : Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659 (1998).
  14. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F. and Slamon, D. : Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241 (1999). https://doi.org/10.1038/sj.onc.1202526
  15. Leyland-Jones, B., Gelmon, K., Ayoub, J. P., Arnold, A., Verma, S., Dias, R. and Ghahramani, P. : Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. 21, 3965 (2003). https://doi.org/10.1200/JCO.2003.12.109
  16. Baselga, J., Carbonell, X., Castañeda-Soto, N. J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C. and Ghahramani, P. : Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol. 23, 2162 (2005). https://doi.org/10.1200/JCO.2005.01.014
  17. Bruno, R., Washington, C. B., Lu, J. F., Lieberman, G., Banken, L. and Klein, P. : Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 56, 361 (2005). https://doi.org/10.1007/s00280-005-1026-z